Pancreatic Cancer Research

ResearcherNorth Dakota State UniversityActive in the last 2 years

Mohiuddin Quadir

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-2811-773X; OpenAlex author ID A5014281779; NIH RePORTER profile ID 14509313. Sources: OpenAlex.

Their work

Papers
7 (first author 0, last author 4)
Trials
0
Grants
1
Labs led
1
Collaborators
26
Papers, trials and grants by year

2019: 3 papers · 2020: none · 2021: 1 paper · 2022: none · 2023: none · 2024: 2 papers · 2025: 1 paper · 2026: 1 grant

Papers 7

  1. Targeted nanoencapsulation of tunicamycin reduces toxicity while improving its therapeutic effectiveness in pancreatic cancer cells. Co-author DOI 10.1016/j.omton.2025.201047↗
  2. pH-responsive targeted nanoparticles release ERK-inhibitor in the hypoxic zone and sensitize free gemcitabine in mutant K-Ras-addicted pancreatic cancer cells … Co-author DOI 10.1371/journal.pone.0297749↗
  3. Extracellular Signal-Regulated Kinase Inhibitor SCH772984 Augments the Anti-Cancer Effects of Gemcitabine in Nanoparticle Form in Pancreatic Cancer Models. Co-author DOI 10.22088/ijmcm.bums.13.3.220↗
  4. pH-Sensitive Nanodrug Carriers for Codelivery of ERK Inhibitor and Gemcitabine Enhance the Inhibition of Tumor Growth in Pancreatic Cancer. Last author DOI 10.1021/acs.molpharmaceut.0c00499↗
  5. Dendritic Polyglycerol-Derived Nano-Architectures as Delivery Platforms of Gemcitabine for Pancreatic Cancer. Last author DOI 10.1002/mabi.201900073↗
  6. Microenvironment-sensing, nanocarrier-mediated delivery of combination chemotherapy for pancreatic cancer. Last author DOI 10.1007/s12079-019-00514-w↗
  7. PEG-b-poly (carbonate)-derived nanocarrier platform with pH-responsive properties for pancreatic cancer combination therapy. Last author DOI 10.1016/j.colsurfb.2018.10.069↗

Grants 1

  1. Biostatistics and Bioinformatics Core Facility P20GM109024↗

Closest collaborators

The 25 strongest of 26 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Katie M. Reindl · 3 shared papers, 1 shared grant, 2019–2026 · strength 0.95
  2. Priyanka Ray · 6 shared papers, 2019–2024 · strength 0.94
  3. Sanku Mallik · 3 shared papers, 1 shared grant, 2019–2026 · strength 0.78
  4. Sushanta K. Banerjee · 4 shared papers, 2019–2025 · strength 0.63
  5. Snigdha Banerjee · 4 shared papers, 2019–2025 · strength 0.63
  6. Megan Orr · 1 shared paper, 1 shared grant, 2021–2026 · strength 0.57
  7. Debasmita Dutta · 3 shared papers, 2021–2025 · strength 0.54
  8. Gauthami Nair · 3 shared papers, 2019–2024 · strength 0.49
  9. Sathish Venkatachalem · 1 shared grant, 2026 · strength 0.46
  10. Jiha Kim · 1 shared grant, 2026 · strength 0.46
  11. Ang Guo · 1 shared grant, 2026 · strength 0.46
  12. Mark T Hamann · 1 shared grant, 2026 · strength 0.46
  13. Roberto Gomes · 1 shared grant, 2026 · strength 0.46
  14. Jagdish Singh · 1 shared grant, 2026 · strength 0.46
  15. Estelle Leclerc · 1 shared grant, 2026 · strength 0.46
  16. John Curlee Wilkinson · 1 shared grant, 2026 · strength 0.46
  17. Elisabetta Liverani · 1 shared grant, 2026 · strength 0.46
  18. Erxi Wu · 1 shared grant, 2026 · strength 0.46
  19. Bin Guo · 1 shared grant, 2026 · strength 0.46
  20. Yongki Choi · 1 shared grant, 2026 · strength 0.46
  21. Guodong Liu · 1 shared grant, 2026 · strength 0.46
  22. Rick J. Jansen · 1 shared grant, 2026 · strength 0.46
  23. Buddhadev Layek · 1 shared grant, 2026 · strength 0.46
  24. Arnab Ghosh · 2 shared papers, 2019–2024 · strength 0.30
  25. Daniel J. Mettman · 1 shared paper, 2025 · strength 0.22

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.